Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon contact icon menu icon
Medicilon Logo
|
search icon close search icon contact icon menu icon
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center

Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells. The pharmacokinetic study of the selective PAK4 inhibitor was carried out by Medicilon

2023-07-11
|
Page View:

1.jpgThe p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic cancer. The pharmacokinetic study of Compound 55 was carried out by Medicilon.

Reference:

Peilu Song, et al. Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells. Acta Pharm Sin B. 2022 Jun;12(6):2905-2922. doi: 10.1016/j.apsb.2022.02.029. 

Return
Relevant News